{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:25Z","timestamp":1787635465795,"version":"build-2736575974"},"reference-count":6,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold> Medicines and Healthcare products Regulatory Agency. Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease. Drug Safety Update 2023;16(10):3.<\/jats:p>","DOI":"10.1136\/dtb.2023.000029","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T13:20:15Z","timestamp":1686835215000},"page":"102-102","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Safety update: febuxostat and CVD"],"prefix":"10.1136","volume":"61","member":"239","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2025082722395534000_61.7.102.1","article-title":"Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease","volume":"16(10)","year":"2023","journal-title":"Drug Safety Update"},{"key":"2025082722395534000_61.7.102.2","article-title":"Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease","volume":"12(12)","year":"2019","journal-title":"Drug Safety Update"},{"key":"2025082722395534000_61.7.102.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0"},{"key":"2025082722395534000_61.7.102.4","unstructured":"OpenPrescribing . Bennett Institute for applied data science, University of Oxford [online]. 2023. Available: https:\/\/openprescribing.net\/ [Accessed 31 May 2023]."},{"key":"2025082722395534000_61.7.102.5","unstructured":"Febuxostat 120 mg film-coated tablets. summary of product characteristics, UK. Tillomed Laboratories Ltd; 2023."},{"key":"2025082722395534000_61.7.102.6","unstructured":"National Institute for Health and Care Excellence . Gout: diagnosis and management (NG219) [online]. 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ng219 [Accessed 31 May 2023]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2023.000029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:40:04Z","timestamp":1756359604000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2023.000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":6,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,28]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/dtb.2023.000029"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2023.000029","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}